From Kinesiology Tape To Pain Treatment Patches, (Nasdaq: NTRB) Is Building A Unique Mix

Every pharma story has a quiet turning point.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored From Kinesiology Tape To Pain Treatment Patches, (Nasdaq: NTRB) Is Building A Unique Mix *Click Here To Get Our Alerts Faster Via SMS* September 24th Greetings Readers, Every pharma story has a quiet turning point. For Nutriband Inc. (Nasdaq: NTRB), it may have arrived in a letter from the U.S. Patent and Trademark Office. The company received a USPTO Notice of Publication for the commercial brand name trademarks of its lead product, an abuse-deterrent fent-a-nyl patch. The notice starts a 30-day opposition window. If no objections are filed, Nutriband says the USPTO is expected to issue a Notice of Allowance. Why does a name matter? You don't brand a product you plan to shelve. Nutriband intends to submit the name and product labeling to the FDA and other international agencies for review. The patch runs on AVERSA™, a platform with issued patents in 46 countries, including the U.S., Europe, Japan, China and Canada. A Health Advances analysis cited by the company points to potential peak annual U.S. sales of $80Mn to $200Mn. Nutriband's brand name trademarks entered USPTO publication. Source: Nutriband Inc. About Nutriband Inc. (Nasdaq: NTRB) Nutriband is an Orlando-based developer of transdermal pharmaceutical products.  Its latest quarterly filing describes two engines. 4P Therapeutics leads AVERSA development. Pocono Pharmaceuticals, a contract manufacturer of topical, transdermal and kinesiology tape products, generates current revenue. The development pipeline reaches beyond fent-a-nyl. AVERSA Buprenorphine and AVERSA Methylphenidate, and 4P Exenatide for type 2 diabetes sit in preclinical stages. Manufacturing partner Kindeva completed commercial scale-up of the fent-a-nyl patch in 2025. Sources And More: NTRB Website. The Market Backdrop: Patches Are Growing Up Precedence Research sizes the global transdermal delivery systems market at $87.46Bn in 2026, with a potential climb to $239.43Bn by 2035. That's an 11.84% CAGR. North America held a 38.60% share in 2025. Abuse risk concentrates in pain management. Nutriband's corporate presentation states that over 70% of fent-a-nyl patch abusers choose oral routes. AVERSA's taste-aversion approach targets that exact pathway. Global transdermal delivery systems market forecast, 2025 to 2035. Source: Precedence Research Behind The Scenes: The Shareholder Meeting Checklist At the January shareholder annual meeting in Orlando, management walked shareholders through a scorecard. The meeting summary credited 2025 with a stronger Kindeva partnership, completed scale-up, new U.S. and Macao patents, and an FDA Type C meeting. The 2026 focus on development towards NDA filing list was just as direct: File nonprovisional patent application to potentially extend patent protection of AVERSA™ technology-based products to 2046 Manufacture clinical supplies for the Human Abuse Liability (HAL) clinical trial File Investigational New Drug (IND) application with the US FDA Initiate Human Abuse Liability (HAL) clinical study Shareholders also elected two new directors, Alessandro Puddu and Viorica Carlig.  For a development-stage company, a written roadmap like this gives you something concrete to measure progress against. The Pivot: AVERSA Heads Abroad Nutriband then looked south. It signed an exclusive distribution agreement with Innomedica for Costa Rica, covering AVERSA Fent-a-nyl upon approval and all of its sports tape products. Innomedica oversees and finances the regulatory approvals. Later, the company announced its AI kinesiology tapes were approved for distribution and sale in Costa Rica. The tape line gets a foreign foothold today, while the patch gains a ready channel for later. Nutriband's exclusive Costa Rica agreement with Innomedica. Source: Nutriband Inc. NTRB's IPO Warrant Overhang Faces A Hard Stop September 30th Capital structure often gets overlooked until it changes. At Nutriband, a change is now close. The company's outstanding 2021 IPO warrants, 910,904 in total with a $6.43 exercise price, are set to expire on September 30th, 2026. Management has confirmed there will be no extension, repricing, or modification of these terms. Holders either exercise before expiration, or the warrants lapse. Why does this matter? For years, these warrants have represented a known source of potential dilution. Their expiration could remove that overhang entirely. The potential result for NTRB is a cleaner share structure. 6 Potential Catalysts Putting (Nasdaq: NTRB) At The Top Of Our Watchlist #1. A Low Float Setup With Heightened Volatility Potential. With Yahoo Finance reporting a float of just 5.28Mn shares, NTRB fits the low float profile, and the potential for heightened volatility may be significant. #2. Twelve Of Thirteen Technical Indicators Flashing Bullish. Barchart's opinion page showed an 88% overall bullish reading for NTRB at the closing bell Thursday. #3. Brand Name Trademarks Enter The USPTO Opposition Window. A Notice of Allowance could follow if no objections are filed, potentially moving NTRB closer to submitting its brand name to the FDA. #4. A Warrant Deadline Carrying $5.86Mn In Potential Proceeds. The company confirmed its 910,904 public warrants at $6.43 expire Sept. 30 without extension or repricing, and NTRB's latest close sits above that strike. #5. A Pipeline Stretching From Pain To ADHD And Diabetes. Beyond fent-a-nyl, the NTRB pipeline includes AVERSA Buprenorphine, AVERSA Methylphenidate and 4P Exenatide, potentially extending the platform into new categories. #6. Insiders Hold A Commanding Share Of The Company. Insiders own approx. 59.09% of NTRB shares on Yahoo Finance, a level of alignment market watchers often track closely. The Bottom Line Nutriband Inc. (Nasdaq: NTRB) isn't a finished story. It's a company with a patented platform, a named product, a manufacturing partner, and a published regulatory roadmap. The next steps are public: clinical supplies, an IND, and a human abuse liability study. We’re initiating coverage on Nutriband Inc. (Nasdaq: NTRB). Keep your eyes peeled for updates coming out soon. Talk again shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 09/24/2026 and ending on 09/28/2026 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred sixty five thousand USD ("Funds"). These Funds were part of the one hundred thirty four thousand USD funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither SWN Media LLC, TD Media LLC and their member own shares of (NTRB:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/ntrb-elb0m/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Constant Contact Data Notice